Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The New Device Incubators

This article was originally published in Start Up

Executive Summary

Today many universities have a mandate to preferentially create new companies around university technologies, rather than stick with straight licensing deals, particularly when it comes to medical devices. What's also new is that universities are making a concerted effort to attract in companies from beyond their hallowed gates to enhance internal research programs. To meet these goals, they're turning to new kinds of incubators, which are essentially service organizations that connect resources in the hands of multiple constituencies to start-up companies. In so doing, incubators are facilitating the process of company creation for individual entrepreneurs, enhancing university tech transfer, and fulfilling regional economic development goals.

You may also be interested in...



Device Incubation: Challenges in Making the Model Work

Device incubators have their proponents and detractors, but remain a constant source of company creation. The big question: is this model sustainable?

In Europe, a Medical Device Accelerator Takes Root

Device giant Medtronic and venture capital leader Sofinnova have teamed up to see if they can help seed the promising ground of device start-ups in Europe, providing an outlet for novel ideas of the continent's physicians.

Corporate Biotech Incubators

Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures

Related Content

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel